
Understanding Medical Device Stakeholders
When designing a new product, identifying medical device stakeholders is a vital first step. As Ariana Wilson and Mark Drlik explain in this episode of MedDevice by Design, every phase of a device’s life cycle involves different people with distinct needs—from clinicians and patients to service technicians and regulatory bodies. Understanding who these stakeholders are and what they value helps create more effective and sustainable designs.
Mapping user needs across the product life cycle
Stakeholders influence a product’s success through purchase, adoption, use, advocacy, and sometimes even rejection. By mapping all involved parties—assembly teams, procurement, distributors, maintenance staff, and end users—designers can visualize where interests overlap or diverge. This mapping process allows teams to identify conflicting needs early and guide design tradeoffs before they become barriers to usability or compliance.
Balancing conflicting stakeholder needs
As Wilson points out, user needs often conflict. A facilities manager may prioritize infection control, while a biomed technician may need quick access for repairs. These needs seem opposed, but they stem from shared goals: safety and efficiency. Recognizing the core requirement behind each helps designers uncover creative ways to satisfy both. Drlik adds that thoughtful design, combined with iterative feedback, can resolve these tensions and sometimes inspire entirely new solutions.
From user insights to design innovation
By interpreting and negotiating stakeholder needs, designers transform requests into actionable design requirements. This process keeps teams focused on solving real problems rather than simply responding to feature requests. As the discussion highlights, creative solutions often emerge when designers fully understand the perspectives of all medical device stakeholders.
Enjoying MedDevice by Design? Sign up to get new episodes sent to your inbox.
Related Resources

Connected health devices are multiplying fast. We examine the gap between remote monitoring’s promise and its reality.

Ariana and Mark walk through what separates a clinical prototype from a proof-of-concept build, what determines how much testing and documentation you actually need, and where the regulatory line between significant risk and non-significant risk falls.

In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.

Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.